...
首页> 外文期刊>World Journal of Oncology >Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer
【24h】

Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer

机译:IIIB期宫颈癌患者新辅助动脉内化疗与同期放化疗的比较

获取原文
           

摘要

Background: The purpose of this study was to compare the long-term survival of patients with stage IIIB squamous cell carcinoma of the cervix treated with neoadjuvant intraarterial chemotherapy (IA-NAC) versus those treated with concurrent chemoradiotherapy (CCRT). Methods: We retrospectively reviewed the clinical records of 38 patients with stage IIIB squamous cell carcinoma of the cervix admitted between January 1994 and December 1999 who received IA-NAC followed by abdominal radical hysterectomy (ARH) or radiotherapy (RT). IA-NAC consisted of bilateral infusion via the internal iliac artery of cisplatin, bleomycin and pirarubicin for 2-3 courses. A historical control group of 64 patients who underwent primary CCRT from January 2000 to September 2007 was used for comparison. Results: In the IA-NAC group, 12 patients (31.6%) with operable tumors underwent ARH, and the remaining 26 patients (68.4%) received RT. The response rates were 86.8% (12 complete response + 21 partial response) for IA-NAC and 98.4% (26 complete response + 37 partial response) for CCRT (P = 0.077), respectively. The 5-year overall survival and disease-free survival rates were 62.4 and 44.5% for IA-NAC and 51.1 and 46.9% for CCRT (P = 0.247 and 0.776), respectively. The 5-year overall survival and disease-free survival rates were 75.0 and 58.3% for the patients receiving IA-NAC followed by ARH, and 55.3 and 37.6% for the patients receiving IA-NAC followed by RT (P = 0.368 and 0.262), respectively. Conclusions: In the present study, IA-NAC followed by ARH or RT and primary CCRT showed similar survival rates for stage IIIB squamous cell carcinoma of the cervix.World J Oncol. 2013;4(6):221-229doi: http://dx.doi.org/10.4021/wjon720w
机译:背景:本研究的目的是比较接受新辅助动脉内化疗(IA-NAC)和同期放化疗的患者的IIIB期宫颈鳞状细胞癌患者的长期生存。方法:我们回顾性回顾了1994年1月至1999年12月收治的38例子宫颈IIIB期宫颈鳞状细胞癌患者的临床记录,这些患者接受IA-NAC,然后行腹部根治性子宫切除术(ARH)或放疗(RT)。 IA-NAC包括通过顺铂,博莱霉素和吡柔比星的bilateral内动脉双侧输注2-3个疗程。比较2000年1月至2007年9月接受CCRT治疗的64例患者的历史对照组。结果:IA-NAC组中,有12例(31.6%)可手术肿瘤患者接受了ARH,其余26例(68.4%)接受了RT。 IA-NAC的缓解率为86.8%(12个完全缓解+ 21个部分缓解),CCRT的缓解率为98.4%(26个完全缓解+ 37个局部缓解)(P = 0.077)。 IA-NAC的5年总生存率和无病生存率分别为CCRT的62.4%和44.5%,CCRT的51.1%和46.9%(P = 0.247和0.776)。接受IA-NAC继之以ARH的患者的5年总生存率和无病生存率分别为75.0和58.3%,接受IA-NAC继之以RT的患者的5年总体生存率和无病生存率分别为55.3和37.6%(P = 0.368和0.262) , 分别。结论:在本研究中,IA-NAC,ARH或RT和原发性CCRT对子宫颈IIIB期鳞状细胞癌的存活率相近。 2013; 4(6):221-229doi:http://dx.doi.org/10.4021/wjon720w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号